Browse > Article
http://dx.doi.org/10.7778/jpkm.2019.33.2.012

The Effect of Coptidis Rhizoma and Glycyrrhiza Uralensis on Lipid Deposition with Nonalcoholic Fatty Liver Disease (NAFLD)  

Ahn, Sang Hyun (Dept. of anatomy, college of Korean Medicine, Semyung University)
Kim, Ki Bong (Dept. of Korean Pediatrics, Korean Medicine Hospital, Pusan National University)
Publication Information
The Journal of Pediatrics of Korean Medicine / v.33, no.2, 2019 , pp. 12-21 More about this Journal
Abstract
Objectives Coptidis Rhizoma and Glycyrrhiza Uralensis are herbs that treat obesity and dampness-phlegm. The aim of this study is to investigate the efficacy of Coptidis Rhizoma and Glycyrrhiza Uralensis on lipid deposition with nonalcoholic fatty liver disease (NAFLD). Methods Male 6-week-old C57BL/6 male mice were divided into three groups: control group (Ctrl), high fat diet group (HFF), and high fat diet with Coptidis Rhizoma and Glycyrrhiza Uralensis extract administration group (CGT). Each 10 mice were allocated to each group (total of 30 mice). All mice were allowed to eat fat rich diet freely throughout the experiment. To examine the effect of Coptidis Rhizoma and Glycyrrhiza Uralensis, we observed weight changes, total cholesterol and glucose levels, lipid blot distributions, PGC-1, p-$I{\kappa}B$, and p-JNK. Results Body weights for all mice were measured and analyzed the difference between the groups. Weight gain was significantly lower in CGT group than the HFF group. Total cholesterol and glucose levels were significantly lower in CGT group. The distribution of lipid blots and positive reaction of PGC-1 were significantly lower in CGT group. The positive reaction of p-$I{\kappa}B$ in hepatic tissues was significantly lower in CGT group. The positive reaction of p-JNK in hepatic tissues was significantly lower in CGT group. Conclusions Coptidis Rhizoma and Glycyrrhiza Uralensis have the effect of improving non - alcoholic fatty liver induced insulin resistance through regulation of lipid metabolism.
Keywords
optidis Rhizoma; Glycyrrhiza Uralensis; NAFLD; insulin resistance; lipid metabolism;
Citations & Related Records
Times Cited By KSCI : 9  (Citation Analysis)
연도 인용수 순위
1 Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 Suppl 1:S5-10.
2 Korea Food & Drug Administration. The press release. Retrieved Nov. 14, 2013. Available from http://www.mfds.go.kr/index.do?mid=675&seq=19618&cmd=v
3 Oh K, Jang MJ, Lee NY, Moon JS, Lee CG, Yoo MH. Prevalence and trends in obesity among Korean children and adolescents in 1997 and 2005. Korean J Pediatr. 2008;51:950-5.   DOI
4 Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-61.   DOI
5 Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28:13-24.   DOI
6 Ahn YJ, Yoon KH, Jo JH, Jang DH, Jung YS, Kim JH, Kim BC, Seok HJ, Yoo JS, Ku JR, Yoon M, Shin SS. Gangjihwan Improves nonalcoholic fatty liver disease in high fat diet-fed C57BL/6N mice. Kor. J. Herbology. 2014;29(2):47-54.   DOI
7 Lee BW. Management of patients with nonalcoholic fatty liver disease with lifestyle modification. Korean Diabetes. 2018;19:82-7.   DOI
8 Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. Ann Pharmacother. 2010;44(10):1655-9.   DOI
9 Tang J, Feng YB, Tsao S, Wang N, Curtain R, Wang YW. Berberine and coptidis rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. J Ethnopharmacol. 2009;126(1):5-17.   DOI
10 Jabbarzadeh Kaboli P, Rahmat A, Ismail P, Ling KH. Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol. 2014;740:584-95.   DOI
11 Ortiz LM, Lombardi P, Tillhon M, Scovassi AI. Berberine, an epiphany against cancer. Molecules. 2014;19(8):12349-67.   DOI
12 Yu M, Tong X, Qi B, Qu H, Dong S, Yu B. Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB. Molecular medicine reports. 2014;9(1):249-54.   DOI
13 Chin LW, Cheng YW, Lin SS, Lai YY, Lin LY, Chou MY, et al. Anti-herpes simplex virus effects of berberine from coptidis rhizoma, a major component of a Chinese herbal medicine, Ching-Wei-San. Arch Virol. 2010;155 (12):1933-41.   DOI
14 Yu YE, Park EY, Jung DH, Byun SH, Kim SC, Park SM. Antibacterial activity of oriental medicinal herb extracts against skin pathogens. Journal of Life Science. 2010;20(7):1143-50.   DOI
15 Miao KL, Zhang JZ, Dong Y, Xi YF. Research progress on the chemical compounds and pharmacology of Sophora flavescens. Natural Product Research Development. 2001;13:69-73.   DOI
16 Kusano G, Shibano M, Watanabe H. Pharmaceutical botanical studies on some Glycyrrhiza species. Yakugaku Zasshi. 2003;123:619-31.   DOI
17 Kim HJ, Bae JY, Jang HN, Park SN. Comparative study on antimicrobial activity of glycyrrhiza uralensis and glycyrrhiza glabra extracts in various country of origin as natural antiseptics. Kor J Microbiol Biotechnol. 2013;41(3):358-66.   DOI
18 Kim SY, Kwon JN, Lee I, Hong JW, Choi JY, Park SH, Kwon MJ, Joo M, Han CW. Research on anti-lipogenic effect and underlying mechanism of laminaria japonica on experimental cellular model of non-alcoholic fatty liver disease. J. Int. Korean Med. 2014:35(2)175-83.
19 Kim HJ, Jang HN, Bae JY, Ha JH, Park SN. Antimicrobial activity, quantification and bactericidal activities of licorice active ingredients. Kor J Microbiol Biotechnol. 2014;42(2):386-92.   DOI
20 Jang YS, Seo JY, kwun MJ, Kwon JN, Lee I, Hong JW, Kim SY, Choi JY, Park SH, Joo M, Han CW. Effect of phaseolus angularis seed on experimental cellular model of nonalcoholic fatty liver disease. Korean J. Oriental Physiology & Pathology. 2013;27(6):802-8.
21 Han CW, Lee JH. Effects of KHchunggan-tang on the nonalcoholic fatty liver disease in palmitate-induced cellular model. J Korean Oriental Med. 2011;32(1):109-20.
22 Kim K, Ko H, Shin S. Diagnostic process analysis of prescribing injinho-tang in non alcohoic fatty liver disease using by AHP. The Journal of the Society of Korean Medicine Diagnostics. 2015;19(3):159-71.
23 Jung YS, Kim JH, Kim BC, Seok HJ, Yoo JS, Ku JR, Yoon KH, Jo JH, Jang DH, Yun HY, Yoon M, Shin SS. Comparison of gangjihwan-1,2,3,4 and combination of gangjihwan-1 and gamisochehwan in the improvement effects of nonalcoholic fatty liver disease in a high fat diet-fed obese mouse model. Kor. J. Herbology. 2014;29(6):149-56.   DOI
24 Seo IB, Ahn SH, Kim KB. The effect of bangpungtongsungsan on insulin resistance induced by non-alcoholic fatty liver disease (NAFLD). J Pediatr Korean Med. 2018;32(4):1-12.   DOI
25 Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-95.   DOI
26 Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-24.   DOI
27 Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129:375-8.   DOI
28 Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-73.   DOI
29 Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820-6.   DOI
30 Son CK. The research of immunological function in liver. J Korean Oriental Med. 2001;22(1):3-9.
31 Park MJ, Kim DI, Lim SK, Choi JH, Kim JC, Yoon KC, Lee JB, Lee JH, Han HJ, Choi IP, Kim HC, Park SH. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1a regulation in vitro and in vivo. Journal of Hepatology. 2014;61:1151-7.   DOI
32 Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366-74.   DOI
33 Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185-94.   DOI
34 Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:370-9.   DOI
35 Baeuerle PA, Baltimore D. NF-${\kappa}B$ - Ten years after. Cell. 1996;87:13-20.   DOI
36 Kim TH. Obesity and fatty liver disease. Korean Journal of Medcine. 2005;68(4):347-50.
37 Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17(14):2115-7.   DOI
38 Cha HY, Ahn SH, Cheon JH, Park IS, Kim JT, Kim KB. Hataedock treatment has preventive therapeutic effects in atopic dermatitis-induced NC/Nga mice under high-fat diet conditions. Evid Based Complement Alternat Med. 2016:1-13.
39 Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634-43.   DOI
40 Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180-8.   DOI